Lirafugratinib FDA Approval Sets Up a Premium-Priced FGFR2 Launch

What the FDA approved

The FDA approved lirafugratinib on September 23, 2026. The drug is an oral kinase inhibitor sold by Elevar Therapeutics as Lyrfigtu. It is cleared for adults with cholangiocarcinoma that was treated before, cannot be removed surgically or has spread, and carries an FGFR2 gene fusion or other rearrangement.22 Patients take 70 mg once a day until the cancer progresses or the side effects become too much.2

The decision arrived four days before the September 27 priority-review deadline.24 Elevar filed its new drug application in January 2026, and the agency granted priority review in March.2 The FDA reviewed it through its Real-Time Oncology Review pilot and the voluntary Assessment Aid. The drug also held breakthrough therapy and orphan drug designations.4

The clinical story is now mostly settled. The commercial story is just starting. Elevar's Korean parent, HLB, has said it expects Lyrfigtu to cost 15 to 20 percent more in the U.S. than the FGFR2 inhibitors already on the market.21 Those drugs are already some of the most expensive targeted cancer pills sold in the country.

The evidence behind the label

The approval rests on the REFOCUS trial (NCT04526106), a multicenter, open-label, single-arm study. The efficacy analysis covered 116 patients with unresectable or metastatic cholangiocarcinoma. All had received chemotherapy or chemoimmunotherapy, and none had taken an FGFR inhibitor.6 An independent review committee found a response rate of about 46% and a median response duration of 11.8 months.6 Elevar also reported median progression-free survival of 11.3 months, with 49.2% of patients free of progression at one year.7

The figures differ slightly by outlet. Data shown at the 2026 ASCO Gastrointestinal Cancers Symposium gave a 46.5% response rate among 114 evaluable patients. That included complete responses in 2.6% and partial responses in 43.9%.3 The FDA's rounded 46% is the regulatory number. The gap reflects different analysis populations, not conflicting results.

The drug's main limits are clear from its own data. A single-arm trial shows that a drug shrinks tumors. It cannot show that patients live longer than they would on another treatment.6 The results also do not cover patients who already took an earlier FGFR inhibitor, because they were left out of the efficacy population.6 The trial overall enrolled 490 participants at 48 sites, but the label is based on a 116-patient subset.23

One regulatory detail has gotten less attention than it deserves. One analysis notes that the FDA notice says lirafugratinib was "approved." The two earlier drugs in the class were granted accelerated approval.24 The FDA notice also says nothing about an accelerated pathway or a required confirmatory trial.23 That matters for pricing power. A drug with regular approval cannot easily be painted by payers as provisional.

Safety: the eye exam is part of the deal

The label warns about eye toxicity, high phosphate levels with soft-tissue mineralization, and harm to a developing fetus.4 Elevar's safety data cover 385 patients. Of those, 31% developed retinal pigment epithelial detachment, with grade 3 events in 1.8%. The median time to onset was 57 days. The condition led to dose interruptions in 15% of patients and dose reductions in 10%.7 Guidance for nurses calls for eye exams, including optical coherence tomography, before treatment starts and regular checks during it.8 MSK also lists more common problems such as hand-foot redness and swelling, mouth sores, nail changes, and dry eyes and mouth.1

All of this monitoring costs money on top of the drug itself. That is easy to miss when the debate centers on the pill's price.

A crowded, narrow market

Lirafugratinib is the third FGFR inhibitor for FGFR2 fusion-positive cholangiocarcinoma. Incyte's pemigatinib (Pemazyre) came first in 2020, followed by Taiho's futibatinib (Lytgobi).24 Elevar's pitch is selectivity. The drug binds FGFR2 permanently and is meant to largely spare the other FGFR family members.25 The company says this lets it block many resistance mutations that arise on older drugs while avoiding off-target side effects.7

The two claims carry different weight. FGFR2 selectivity is part of how the molecule was designed. The resistance-mutation advantage has not been tested head-to-head, and the expert quotes supporting it came through Elevar's own announcement.26 Until clinical data in patients who already took an FGFR inhibitor are reviewed and approved, the drug's on-label role is second-line or later in patients new to the class.24

Oncologists are already asking which FGFR2 drug to use first, not whether to use one. No head-to-head data exist. Doctors are left comparing results across different trials, resistance profiles and tolerability.9 Some favor futibatinib first because its survival figures looked somewhat better than pemigatinib's in FIGHT-202.9 Chih-Yi "Andy" Liao, whose institution took part in REFOCUS, said the three drugs cannot be ranked directly because they were studied in different populations. He added that each has a place in practice.10

The patient pool is small. About 8,000 people in the U.S. are diagnosed with bile duct cancer each year, according to Elevar.7 Estimates of how many tumors carry FGFR2 changes vary. MSK puts it at 10% to 20% of bile duct cancers.1 Other reports put fusions at roughly 10% to 15%26 or 10% to 16% of intrahepatic cases specifically. The second reading is the more precise one. It suggests the eligible U.S. population each year is in the hundreds, not the thousands.

The price question

Elevar had not announced a price at approval.26 As of September 2026, no wholesale acquisition cost, cost-effectiveness analysis or health technology assessment for lirafugratinib had been published. HLB has now said it plans a fourth-quarter U.S. launch at a 15 to 20 percent premium over its rivals.21

Here is what that means in rough numbers. A 2023 survey of U.S. kinase inhibitor prices put futibatinib at about $44,000 a month, or roughly $528,000 a year. Pemigatinib came in around $27,000 a month, about $324,000 a year.11 Those were cash prices from an online pricing site and did not reflect insurance, so they are rough guides.11 Still, a 15 to 20 percent premium over the pricier rival would mean more than $50,000 a month at those prices. A premium over pemigatinib would land in the low $30,000s. This is my own arithmetic on older reference prices, not a disclosed list price. The real number will depend on which rival HLB uses as its benchmark.

The premium plan shows a strategy, not just a hope. Elevar is charging more for a newer drug with a regular approval, a selectivity story and an unproven resistance claim. It is doing so before any head-to-head data exist. The market it is entering is real but modest. Pemigatinib and futibatinib together had sales of about 203 billion won ($151 million) last year, according to HLB.19 Pemazyre alone brought in roughly $82 million in 2024.20 In a market that small, a newcomer can earn more by charging a high price per patient than by competing for volume.

Why payers may push back

Outside the U.S., health agencies have already pushed back on this drug class. Canada's drug agency estimated that pemigatinib costs $15,499 per 28 days. It also estimated that finding one eligible patient takes about $38,000 in testing.12 England's NICE lists pemigatinib at an annual cost of about £124,430. When NICE recommended futibatinib, it was largely because its cost was similar to pemigatinib's under confidential discounts. That suggests rough price parity, not a premium, is how payers there expect this class to behave.13 A Taiwanese study found pemigatinib cost-effective only if its hypothetical price was cut by about half.14

Treatment costs pile up in other ways too. Patients stay on the drug until progression, which came at a median of 11.3 months in the pivotal cohort. In one commercially insured U.S. group with advanced biliary tract cancer, all-cause costs averaged $22,617 per patient per month during second-line therapy. Lirafugratinib's list price will sit on top of costs that are already high.

Elevar has also applied to the European Medicines Agency.2 That means the premium strategy will soon meet health systems that compare cost against benefit directly. There, a single-arm trial with no survival comparison is a weak basis for a higher price. Pricing on that model is mostly a U.S. option.

Who profits

The deal behind the drug shows how value is split. Relay Therapeutics discovered lirafugratinib, then known as RLY-4008. It licensed the drug worldwide to Elevar in December 2024.24 By June 30, 2026, Relay had received $18.7 million. It can still earn up to $485 million in milestones plus tiered royalties.23 Elevar is majority-owned by HLB.24 Higher pricing therefore pays off for the Korean parent and, through royalties, for the U.S. company that created the molecule.

The bottom line

Lyrfigtu clearly helps a small group of bile duct cancer patients. About half saw their tumors shrink, and responses lasted close to a year. It arrives in a class where doctors still have no direct comparisons to guide them. My reading is that its pricing will be set by the drug's regulatory status and its selectivity story, not by proven superiority. U.S. buyers will pay for the novelty first. Payers abroad, and eventually any head-to-head data, will show whether the premium is earned.